PharmaPoint:纖維肌痛 - 全球醫藥品預測、市場分析
PharmaPoint: Fibromyalgia - Global Drug Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 220 Pages
|PharmaPoint:纖維肌痛 - 全球醫藥品預測、市場分析 PharmaPoint: Fibromyalgia - Global Drug Forecast and Market Analysis to 2023|
|出版日期: 2015年05月01日||內容資訊: 英文 220 Pages||
The fibromyalgia market is relatively new and not yet established. Three drugs currently dominate the sales across the 7MM and form the core treatment options; Lyrica, Cymbalta and Savella are all approved in the US while only the former is approved in Japan. Since these drugs are also available in the 5EU for other indications, they are prescribed as off-label therapies. A handful of other genericized products also provide off-label usage including antidepressants, anti-epileptics, opioids and muscle relaxants. Although Lyrica, Cymbalta and Savella can provide an effective treatment regimen, there are ample opportunities for the development of alternative treatment choices which can expand the medications available to patients, providing improvement in efficacy, safety and compliance. By 2023, there will be four new entrants to the market (Lyrica CR, TNX-102 SL, DS-5565 and TD-9855). These new products will help to drive market growth and offset some of the patent expiries of the leading brands during the forecast period. Despite these advancements in the treatment landscape, fibromyalgia therapeutic sales growth are expected to be minimal.